DDInter82 DDInter927
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Amoxapine {u} (Compound) resembles {v} (Compound) Chlordiazepoxide
Amoxapine {u} (Compound) resembles {v} (Compound) Lorazepam
Amoxapine {u} (Compound) binds {v} (Gene) HTR7
Amoxapine {u} (Compound) upregulates {v} (Gene) MSMO1
Amoxapine {u} (Compound) causes {v} (Side Effect) Flatulence
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Amoxapine (Compound) resembles Chlordiazepoxide (Compound)
Amoxapine (Compound) resembles Lorazepam (Compound)
Amoxapine (Compound) binds HTR7 (Gene)
Amoxapine (Compound) upregulates MSMO1 (Gene)
Amoxapine (Compound) causes Flatulence (Side Effect)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amoxapine may lead to a major life threatening interaction when taken with Macimorelin
Amoxapine may lead to a major life threatening interaction when taken with Anagrelide